Primary Record
Bictegravir
Note: Only for scientific research or as raw materials for production.
- In stock
- 1,461 g
- Purity
- 98.3 %
- CAS
- 1611493-60-7
Compound Identifiers & Properties
- CAS
- 1611493-60-7
- PubChem CID
- 90311989
- SMILES
- C1C[C@@H]2C[C@H]1N3[C@H](O2)CN4C=C(C(=O)C(=C4C3=O)O)C(=O)NCC5=C(C=C(C=C5F)F)F
- Canonical SMILES
- O=C(NCc1c(F)cc(F)cc1F)c1cn2c(c(O)c1=O)C(=O)N1[C@H]3CC[C@H](C3)O[C@@H]1C2
Names & Synonyms
- Bictegravir
- bictegravirum
- Bictegravin
- 1611493-60-7
- Bictegravir sodium
- Bictegravir [INN]
- Bictegravir?
- GS-9883
- Bictegravir (Standard)
- Bictegravir [USAN:INN]
- BICTEGRAVIR [MI]
- RefChem:568041
- 8GB79LOJ07
- UNII-8GB79LOJ07
- Bictegravir (USAN/INN)
- Bictegravir, (+/-)-
- BICTEGRAVIR [USAN]
- RY7J24S9ZL
- BICTEGRAVIR [WHO-DD]
- C21H18F3N3O5
- CHEBI:172943
- GS-9883-01
- DTXSID701027937
- CHEMBL3989866
- SCHEMBL15914278
- GS 9883
- GTPL11575
- MFCD31536971
- SOLUWJRYJLAZCX-LYOVBCGYSA-N
- BDBM330048
- DTXCID901513504
- AMY12383
- BCP25703
- EX-A3161
- Bictegravir (100 mg/mL in DMSO)
- EBC-27122
- GS9883
- HY-17605R
- s5911
- AKOS032954062
- C21-H18-F3-N3-O5
- DB11799
- DT-0020
- (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
- AC-30658
- DA-51105
- HY-17605
- NB166284
- CS-0014685
- NS00073631
- J3.723.130D
- D10909
- N16998
- (1S,11R,13R)-5-hydroxy-3,6-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-12-oxa-2,9-diazatetracyclo[11.2.1.02,11.04,9]hexadeca-4,7-diene-7-carboxamide
- US9663528, 42
- A902376
- EN300-22793610
- F805020
- Q27270406
- B2693-058383
- 2,5-Methanopyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazepine-10-carboxamide, 2,3,4,5,7,9,13,13a-octahydro-8-hydroxy-7,9-dioxo-N-((2,4,6-trifluorophenyl)methyl)-, (2R,5S,13aR)-
- GS-9883; GS 9883; GS9883; GS-9883-01
- hydroxy-dioxo-N-[(2,4,6-trifluorophenyl)methyl][?]carboxamide
- 2,5-Methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide, 2,3,4,5,7,9,13,13a-octahydro-8-hydroxy-7,9-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-, (2R,5S,13aR)-
- (1S,11R,13R)-5-hydroxy-3,6-dioxo-N-((2,4,6-trifluorophenyl)methyl)-12-oxa-2,9-diazatetracyclo(11.2.1.02,11.04,9)hexadeca-4,7-diene-7-carboxamide
- (1S,11R,13R)-5-Hydroxy-3,6-dioxo-N-(2,4,6-trifluorobenzyl)-12-oxa-2,9-diazatetracyclo[11.2.1.02,11.04,9]hexadecane-4,7-diene-7-carboxamide
- (1S,11R,13R)-5-hydroxy-3,6-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-12-oxa-2,9-diazatetracyclo[11.2.1.0(2),(1)(1).0?,?]hexadeca-4,7-diene-7-carboxamide
- (1S,11R,13R)-5-hydroxy-3,6-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-12-oxa-2,9-diazatetracyclo[11.2.1.0^{2,11}.0^{4,9}]hexadeca-4,7-diene-7-carboxamide
- (2R, 5S, 13aR) - 8- Hydroxy- 7, 9- dioxo- N- (2, 4, 6- trifluorobenzyl) - 2, 3, 4, 5, 7, 9, 13, 13a- octahydro- 2, 5- methan opyrido[1', 2':4, 5] pyrazino[2, 1- b] [1, 3] oxazepine- 10- carboxamide
- (2R,5S,13aR)-2,3,4,5,7,9,13,13a-Octahydro-8-hydroxy-7,9-dioxo-N-((2,4,6-trifluorophenyl)methyl)-2,5-methanopyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazepine-10-carboxamide
- (2R,5S,13aR)-2,3,4,5,7,9,13,13a-Octahydro-8-hydroxy-7,9-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
- (2R,5S,13aR)-7,9-dioxo-10-[(2,4,6-trifluorobenzyl carbamoyl]-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate
- (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2, 1-b][1,3]oxazepine-10-carboxamide
- (2RS,5SR,13aRS)-2,3,4,5,7,9,13,13a-Octahydro-8-hydroxy-7,9-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
- 2,5-Methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide, 2,3,4,5,7,9,13,13a-octahydro-8-hydroxy-7,9-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-, (2R,5S,13aR)-rel-
- BIC
- KLQ
- rel-(2R,5S,13aR)-2,3,4,5,7,9,13,13a-Octahydro-8-hydroxy-7,9-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide